Corvus Pharmaceuticals announced on April 9, 2025, the appointment of Richard van den Broek, managing partner at HSMR Advisors, to its Board of Directors. Mr. van den Broek brings over 30 years of experience in the life sciences industry, encompassing roles as an investor, biotechnology equity research analyst, and board member.
Mr. van den Broek's prior board experience includes serving on the board of Pharmacyclics, Inc. through its acquisition by AbbVie in 2015, where he contributed to bringing the first BTK inhibitor to market. His expertise is expected to provide valuable guidance as Corvus advances its clinical pipeline.
The company emphasized that Mr. van den Broek's deep understanding of the global pharmaceutical market and proven track record in the biotechnology sector will be instrumental. His appointment is intended to strengthen the company's strategic direction and leverage the unique opportunities provided by ITK inhibition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.